Table 3

Summary of biological and clinical information of patients characterized by GD2neg/low NB variants

IDAge at diagnosis (months)INRG (stage)Sites of metastases at diagnosisRisk groupMYCN statusCHG array profileHistopathological
diagnosis		Previous administration of anti-GD2 immunotherapyAge at relapse (months)Sites of relapse
3372 53MNAHRNot amplifiedSCANB, Schwannian stroma poor, undifferentiated. Unfavorable histology according to INPC.No194Tumor humerus lesion
(soft tissues, bone marrow and skeleton)
4701 139MBone marrow and skeletonHRNDNDNB, Schwannian stroma poor, poorly differentiated. Unfavorable histology, according to INPC.Yes169Bone marrow and skeleton
ID Other information
3372 CA on BM aspirates at diagnosis

  • Negative


IC analysis with anti-GD2 on BM aspirates at diagnosis:

  • Presence of non-convincingly interpretable cells (NCICs) according to published criteria for IC detection13


IHC analysis on tumor at relapse (humerus bone metastasis):

  • CD56, synaptophysin and TH: positive

  • Chromogranin and Phox-2b: negative


Vimentin, cytokeratins, CD99, WT1: negative
4701 IHC analysis on BOM at diagnosis:

  • CD56, chromogranin and Phox-2b: positive


IHC analysis on tumor mass residual from chemotherapy

  • CD56, NB84, TH and Phox-2b: positive

  • INPC, International Neuroblastoma Pathology Classification; NA, not available; ND, not determined; SCA, segmental chromosomal aberrations.